|
Safety and Tolerability Study of Drug to Treat Schizophrenia Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about Safety and Tolerability Study of Drug to Treat Schizophrenia conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Safety and Tolerability Study of Drug to Treat Schizophrenia Clinical research trials and Safety and Tolerability Study of Drug to Treat Schizophrenia health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including Safety and Tolerability Study of Drug to Treat Schizophrenia. Safety and Tolerability Study of Drug to Treat Schizophrenia Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Safety and Tolerability Study of Drug to Treat Schizophrenia clinical trial. Test subjects typically receive the most expert healthcare available for their Safety and Tolerability Study of Drug to Treat Schizophrenia condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Safety and Tolerability Study of Drug to Treat Schizophrenia  Safety and Tolerability Study of Drug to Treat Schizophrenia
Safety and Tolerability Study of Drug to Treat Schizophrenia
For Condition: Schizophrenia
Status: No longer recruiting
Sponsor(s): Sumitomo Pharmaceuticals America ,
Synopsis: The purpose of this study is to evaluate the long-term safety of SM-13496 in patients with schizophrenia.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Single Blind, Dose Comparison, Parallel Assignment, Safety Study
Minimum Age/Maximum Age: 18 Years/64 Years
Genders: Both
Protocol Entry Criteria: Inclusion criteria: - Successful completion of participation in Sumitomo protocol #D1050049 Exclusion criteria: - Substance abuse - Prolactin level of 200ng/mL at baseline - Pregnancy
Total Enrollment: 150
Location and Contact Information:
Carman Research
Smyrna, Georgia, 30080
United States
Comprehensive Clinical Research CNS, PC
Clementon, New Jersey, 08021
United States
Comprehensive Neuroscience. Inc.
Melbourne, Florida, 32935
United States
FutureSearch Trials
Austin, Texas, 78756
United States
Sharp Mesa Vista Hospital
San Diego, California, 92123
United States
Community Clinical Research
Austin, Texas, 78756
United States
Segal Institute for Clinical Research
Miami, Florida, 33161
United States
Atlanta Center for Medical Research
Atlanta, Georgia, 30308
United States
University Hills Clinical Research
Dallas, Texas, 75235
United States
Optimum Health Services
La Mesa, California, 91942
United States
Institute for Psychopharmacology Research
Cerritos, California, 90703
United States
Hawaii Research Center
Honolulu, Hawaii, 96826
United States
American Medical Research
Oakbrook, Illinois, 60523
United States
CNS, Inc.
Falls Church, Virginia, 22041
United States
ClinSearch, Inc.
Kenilworth, New Jersey, 07033
United States
Centers for Behavioral Health, LLC
Rockville, Maryland, 20850
United States
Comprehensive Neuroscience. Inc.
Washington D.C., District of Columbia, 20016
United States
Affiliated Research Institute
San Diego, California, 92108
United States
Quantum Clinical Services Group
Philadelphia, Pennsylvania, 19139
United States
Claghorn Lesem Research Clinic, Inc.
Bellaire, Texas, 77401
United States
Northwest Clinical Research Center
Belleview, Washington, 98004
United States
Additional Information:
Study ID Numbers: D1050174;
Study Start Date: September 2002
Record last reviewed: May 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00044005
Other Schizophrenia Studies:
1. Evaluation of the Genetics of Bipolar Disorder
2. Depakote ER plus an atypical antipsychotic vs. an atypical antipsychotic alone in the treatment of schizophrenia
3. Open label trial exploring a switch from oral medications, to risperidone depot microspheres
4. Glycine and D-Cycloserine in Schizophrenia
5. Imaging of Brain Receptors in Healthy Volunteers and in Patients with Schizophrenia
Related Studies:
Other Schizophrenia Clinical Trials
Other Illinois Clinical Trials
Other Oakbrook Clinical Trials
Safety and Tolerability Study of Drug to Treat Schizophrenia
|
|
|
|
|
|
|
|
